Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases

• Published in: Aging clinical and experimental research 2012-06, Vol.24 (3), p.273-277
• Main Authors: Sciascia, Savino, Piras, Doloretta, Baldovino, Simone, Russo, Alessandra, Naretto, Carla, Rossi, Daniela, Alpa, Mirella, Roccatello, Dario
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Autoimmune diseases; Case Report; Diabetes Mellitus, Type 2 - drug therapy; Drug dosages; Female; Follow-Up Studies; Geriatrics/Gerontology; Giant Cell Arteritis - drug therapy; Giant Cell Arteritis - metabolism; Glucocorticoids - therapeutic use; Histopathology; Humans; Hypertension; Immunosuppressive Agents - therapeutic use; Inflammation; Laboratories; Male; Medicine; Medicine & Public Health; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - therapeutic use; Osteoporosis; Patients; Steroids - administration & dosage; Vein & artery diseases; Veins & arteries
• ISSN: 1594-0667; 1720-8319
• DOI: 10.1007/BF03325257

Background and aims : Glucocorticoids have never been studied in a placebo-controlled manner in giant cell arteritis (GCA), but their effectiveness is well established. However, evidence for the efficacy of immunosuppressant drugs as steroid-sparing agents in this disease is highly desirable, especially in elderly patients. We report the use of mycophenolate mofetil (MMF) as a steroid-sparing agent in three patients (mean age 78 years) with GCA, at high risk of longterm high dose glucocorticoids because of type II diabetes mellitus, obesity, hypertension or osteoporosis. Methods : clinical monitoring and assessment of laboratory parameters were carried out weekly (first month) and then patients were seen in the clinic every 2 weeks. Vascular lesions were also monitored at the onset and during the follow-up by Doppler ultrasonography (every 3 months). Results : all three patients showed clinical benefit, and were also able to taper steroid use to a more rapid regimen compared with the recently suggested steroid reduction approach. MMF was well tolerated, and no signs of toxicity were observed in a mean of 21.6 months (12-29) of follow- up. Conclusion : mycophenolate mofetil may be considered a steroid-sparing agent in elderly patients with GCA but, before results of controlled trials become available, MMF may be considered only for patients who do not improve or stabilize with conventional therapy, or in patients for whom reduced steroid dosage is highly recommended.